Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Novel candidate drugs in anti-tumor necrosis factor refractory Crohn’s diseases: in silico study for drug repositioning


Biologicals like anti-tumor necrosis factor (TNF) therapy for Crohn’s disease (CD) are safe and effective but there is a significant rate of primary and secondary nonresponse in the patients. In this study, we applied a computational approach to discover novel drug therapies for anti-TNF refractory CD in silico. We use a transcriptome dataset (GSE100833) for the anti-TNF refractory CD patients from NCBI GEO. After co-expression analysis, we specifically investigated the extent of protein–protein interactions among genes in clusters based on a protein–protein interaction database, STRING. Pathway analysis was performed using the clEnrich function based on KEGG gene sets. Co-expressed genes in cluster 1, 2, 3, 4, up or down-regulated genes and all differentially expressed genes are highly connected. Among them, cluster 1, which is highly enriched for chemokine signaling, also showed enrichment for cytokine–cytokine receptor interaction and identifies several drugs including cyclosporin with known efficacy in CD. Vorinostat, histone deacetylase inhibitors, and piperlongumine, which is known to have inhibitory effect on activity of NF-κB, were also identified. Some alkaloids were also selected as potential therapeutic drugs. These finding suggest that they might serve as a novel therapeutic option for anti-TNF refractory CD and support the use of public molecular data and computational approaches to discover novel therapeutic options for CD.


Crohn’s disease (CD) involves chronic and progressive transmural inflammation of the bowel characterized by repeated periods of remission and deterioration1. Pharmacologic management of CD currently consists of 5-aminosalicylic acid, corticosteroids, purine analogs azathioprine, and 6-mercaptopurine, and biologics including anti-tumor necrosis factor (TNF)-α inhibitors. Although the medical armamentarium continuously expands, some patients remain refractory to current therapeutic strategies.

Biologicals like anti-TNF agents (e.g., infliximab and adalimumab) are safe and effective but there is a significant rate of primary and secondary nonresponse affecting about 36–40% of patients2,3,4. Currently, anti-a4-integrins, natalizumab and vedolizumab, are generally well tolerated, and a therapeutic option available for those patients5,6. Another numerous other agents for IBD treatment are currently under investigation, including Janus kinase inhibitors, anti-mucosal vascular address in cell adhesion molecule-1 agents, an anti-SMAD7 antisense oligonucleotide, an anti-interleukin-12/23 monoclonal antibody, and a sphingosine-1-phosphate receptor-1 selective agonist. However, these are limitations that make this treatment not always satisfactory. In addition, other therapeutic options with different mechanisms of action are required. Accordingly, additional novel drugs, which have potentially favorable clinical effects in these patients, are needed.

In this study, we applied a computational approach to discover novel drug therapies for CD in silico using publicly available molecular data measuring gene expression in CD samples and 164 small-molecule drug compounds.


Co-expressed genes for intra-cluster interactions

A total of 260 differentially expressed genes (DEGs) were identified (Supplementary Table S1). The consensus clustering algorithm determined an optimal number of four clusters (Fig. 1). The results demonstrate that co-expressed genes in cluster 1, 3, up or down-regulated genes and all DEGs have higher interrelatedness among them and vice versa for other genes clusters (Table 1). Based on the ratio of actual interaction and expected interaction, the connectivity between genes in cluster 1 (with ratio value 4.343) and 3 (with ratio value 9.500), is higher than those in other clusters (Table 1).

Figure 1
figure 1

The enrichment scores are shown based on different clusters, up-regulated, down-regulated and DEGs. And the score is correlated with the depth of color. In the x axis, the up-regulated clusters are colored red, while down-regulated clusters are colored green and cluster containing all DEGs is colored blue. The ranked pathways are shown in the y axis used for clusters containing down-regulated genes.

Table 1 Summary of interactions within clusters for GSE100833.

PPI network and molecular complexes

Perturbed genes that participate big functional clusters are important for studying the mode of action of drugs. A gene/protein interaction network was constructed within each cluster using the STRING (Supplementary Fig. S1). The degree of each node was calculated based on the number of its connections to other nodes and the confidence score cutoff was set as 900 for the analysis. Through Walktrap algorithm analysis, the cluster 1 with the highest degree of association was obtained and 11 subnetworks, including a continent subnetwork, were generated.

Gene clusters based pathways analysis

To determine the co-expressed genes enrichment in biological pathways, the KEGG analysis was performed on co-expressed gene clusters7. It was observed that all the co-expressed genes in all the clusters are highly enriched in inflammatory signaling pathways (Fig. 2). The enrichment scores show that the co-expressed upregulated genes in cluster 1 were highly enriched in chemokine signaling, cytokine–cytokine receptor interaction and toll like receptor signaling pathway (Supplementary Fig. S2), while a small fraction of co-expressed downregulated genes in cluster 4 were enriched in nitrogen metabolism pathways. The upregulated genes in cluster 3 are also observed to be enriched in peroxisome proliferator-activated receptors (PPAR) signaling pathways.

Figure 2
figure 2

The KEGG pathway analysis results. The enrichment scores are shown based on different clusters, up-regulated, down-regulated and DEGs. In the x axis, the up-regulated clusters are colored red, while down-regulated clusters are coloured green and cluster containing all DEGs is coloured blue. The ranked pathways are shown in the y axis.

Drug repositioning analysis

The results show a high enrichment score in cluster 1 for CP-690334-01 drug profile which is not available for its information (Fig. 3). Following that, cyclosporine, vorinostat and with aferin drug profiles shows the same and second highest enrichment profiles in cluster 1. (Fig. 3). The drug-response associated genes are shown in Supplementary Fig. S3. CMap drug signatures matching cluster 2 were also investigated (Fig. 4) and 11 drug candidates with same enrichment score of the DEGs were selected as follows: metronidazole, ethosuximide, famprofazone, 2,6-dimethylpiperidine, prestwick, betonicine, clomipramine, finasteride, mexiletine, zidovudine, and ciclacilline.

Figure 3
figure 3

Drug repositioning results based on cluster 1. Enriched drugs with the instance number are shown on the y axis.

Figure 4
figure 4

Drug repositioning results based on cluster 2. Enriched drugs with the instance number are shown on the y axis.

Cluster 3 does not show any significant drug profile enrichments, despite of its highly enriched for PPAR signaling pathway. We also observed several candidate drug enrichment profiles (pf-00539758-00, clotrimazole, etanidazole, exisulind, lovastatin, myosmine, pentamidine, prochlorperazine, and sodium phenylbutyrate) in cluster 4, which was enriched in nitrogen metabolism pathway (Fig. 5). However, the ranks of the drugs are relatively lower compared with ranks of drugs in cluster 1 and 2 (Fig. 5).

Figure 5
figure 5

Drug repositioning results based on cluster 4. Enriched drugs with the instance number are shown on the y axis.


To the best of our knowledge, this was the first study to predict the drug candidate compounds for anti-TNF refractory CD using CMap-based compound target prediction. Three biologically related groups of pathways, which have an established role in CD, are highlighted in clusters 1 shown in Fig. 2. The chemokine signaling pathway and cytokine–cytokine receptor interaction pathway play important roles in the pathogenesis of CD8. Toll-like receptors, as sensors of gut microbiota, play a critical role in maintaining the gut’s homeostasis and controlling the immune responses, thereby inciting CD9,10. They have been targeted by biologic drugs for the treatment of CD with some success11,12,13.

We focus our repositioning analysis on cluster 1. Cluster 1, which is highly enriched for chemokine and cytokine receptor interaction, identifies relatively many drug profile enrichments. Also, it is notable that the pathways represented in cluster 1 are now the focus of biologic therapies in CD, perhaps in response to the lack of efficacy of small molecule therapies in these pathways.

The information of CP-690334-01, ranked 1st, is not available, however the overrepresentation in anti-TNF refractory CD patients could give us a clear vision when applied to murine model and real patient. An FDA-approved drug for CD, cyclosporin, is captured and ranked 2nd. The data with respect to the use of cyclosporin in CD are very limited. However, recent Australian prospective study shows that a combination strategy of tacrolimus or cyclosporin with vedolizumab was safe and effective when the induction therapy was introduced to CD patients who had failed vedolizumab monotherapy14. This suggests that salvage therapy using cyclosporin may be a strategy to induce remission in to anti-TNF refractory CD patients.

Next, several histone deacetylase inhibitors (HDACi) were identified as potential candidate drugs. Vorinostat are approved for treating certain haematological malignancies, however, recent evidence also illustrates they are modulators of the immune system15,16,17. Therefore, there is emerging evidence that HDACi could have utility in the treatment of rheumatoid arthritis18,19,20, multiple sclerosis21, systemic lupus erythematosus22,23, and airway hyperresponsiveness24, sharing some clinical similarity with CD. There is solid evidence that in in various colitis models in particular, HDACi exert an anti-inflammatory capacity. Several preclinical studies from experimental colitis models reported that the HDACi ameliorated macroscopic and histologic inflammation, in addition to reduced IFN-γ production accompanied by increased production of IL-1025,26,27. Rather, one naturally occurring HDACi, butyrate, decreased TNF production and proinflammatory cytokine mRNA expression by intestinal biopsies and isolated lamina propria cells from CD patients28. Trichostatin A, another HDACi, induce anergy in Th cells in vitro, as characterized by an inhibition of proliferation accompanied by a reduction of IL-2 production in Th1 cell cultures29. These results that have identified the anti-inflammatory effect of HDACi also support a therapeutic role for CD.

Timely, phase I/II clinical trial is currently recruiting the patients to study the safety and efficacy of vorinostat in treating patients with moderate-to-severe CD who are not controlled by standard maintenance therapy (Clinical Trial ID, NCT03167437). Therefore, providing the efficacy, we expect that novel drug would be available soon.

Corticosteroid, such as withaferin A, rimexolone, etynodiol, fluticasone and halcinonide, is effective treatments for CD, but its systemic use has been widely replaced in the clinic by biologics, due to a shared adverse event risk.

Some alkaloids were also selected as potential therapeutic drugs. Chelidonine has several known therapeutic effects, which include mild analgesic, antimicrobial, and oncostatic effects, and it acts as a sedative in the central nervous system30. Further, previous Korean study suggest the chelidonine ameliorates colon injury and inhibits the increase of inflammatory mediators, such as IL-6 and TNF-α, and oxidative damage in murine colitis model31. Harris et al.32 found that papaverine, another alkaloid, attenuated the disease activity index, in large part by significantly reducing rectal bleeding in DSS-induced colitis model. And there are few studies reporting on the anti-inflammatory activity of ethaverine, the ethyl analogue of papaverine. These results provide novel insights into the pharmacological actions of alkaloid and its potential use for the treatment of intestinal inflammation.

Previous study suggest that piperlongumine, a natural product isolated from the fruit, might modulate reactive oxygen species production under inflammatory conditions for rheumatoid arthritis33. The vast majority of literature studies have confirmed beneficial effects of PPAR agonists, such as troglitazone, on macroscopic and histopathological features of colitis34,35,36. However, supporting evidence for therapeutic potential is still limited in remained compounds of cluster 1, compounds enriched for PPAR signaling pathways (cluster 3), and compounds revealed enrichment of nitrogen metabolism pathway (cluster 4).

Several limitations of our study merit discussion. First, biological entities are nonlinear systems showing ‘chaotic behaviour'. As such, there is no relation between the magnitude of the input and the magnitude of the output, with even the most minuscule differences between initial conditions rapidly translating into major differences in the output. And second, there is potentially selection bias from single dataset, which would make the study unrepresentative of the entire anti-TNF refractory CD patients and may restrict the generalizability of our results. Therefore, our computational method would not be able to fully model the complexity of biological systems in CD patients with various confounding factors. Further experiments would therefore need to be performed in multiple, genetically diverse patient samples to confirm this.

In conclusion, among the top compounds predicted to be therapeutic for anti-TNF refractory CD patients by our approach were cyclosporine, a calcineurin inhibitors known to treat IBD, and vorinostat, a HDACi previously described to demonstrate positive results in numerous murine studies. Further, chelidonine and piperlongumine are also identified as potential candidates. These drugs could lead to in-human clinical trials and rapidly and relatively inexpensively offer several new treatments for patients with anti-TNF refractory CD. Since the results are based on in silico analysis, further in-depth studies are necessary to add to the validity of these results.


Data sources and processing

Transcriptomic profiles dataset GSE100833 of anti-TNF refractory CD patients was downloaded from NCBI's Gene Expression Omnibus database (GEO datasets). A total of 327 patients consisting of non-inflamed and inflamed colonic tissues were profiled based on Affymetrix Human Genome U133 Plus 2.0 microarrays platform37. Each gene expression profile was normalized using robust multi-array average (RMA)38,39 and non-expressed and non-informative genes were filtered using the MetaDE package40. The limma package41 was used to identify differentially expressed genes with the thresholds of FDR less than 0.05 and absolute logFC more than 1. Co-expression analysis was performed using the coExp function. We have constructed a drug repositioning and drug mechanism-of-action (MoA) discovery pipeline based on the cogena framework using a pathway gene set and the CMap gene set42.

Consensus clustering

We used partitioning around medoids (PAM) clustering based on Euclidean distance, in order to identify the characteristics of gene expression profiles43. For the choice of cluster number, ConsensusClusterPlus R-package44 was used to identify clusters using 1,000 iterations (reps), 80% sample resampling (pItem) from 2 to 20 clusters (k). The distance matrix was set to Pearson correlation (distance) and linkage function was set as wald. D (innerLinkage) and average (finalLinkag). In order to select optimal cluster number k, we calculated the empirical cumulative distribution (CDF) and the proportional area change under CDF (Δ(k)). According to the Δ(k) vs k plot, the k where Δ(k) started to approach zero was optimal. We also plotted the heatmap of consensus matrix at k to observe whether boundaries of each cluster were sharp. Considering the results of the Δ(k) vs k plot and the heatmap, we determined the optimal cluster numbers.

Connectivity map query

To find compounds that have similar gene expression patterns, we identified the most significantly (Z < 0.001) up- and down-regulated probes based on log ratio of gene expression of adjacent normal tissue, compared with the inflammatory lesions in anti-TNF refractory CD patients. After removal of duplicates, we ended up with 193 up-regulated genes and 65 down-regulated genes (Supplementary Table S2) that we submitted simultaneously for our CMap query (build02; Each signature was queried against the CMap using the gene set enrichment analysis algorithm45,46. By inputting a gene-expression profile of interest and querying it against the CMap data, a list of ranked CMap drugs is obtained (Supplementary Table S3).

Protein–protein interactions and pathway analysis

Following co-expression analysis, we specifically investigated the extent of protein–protein interactions among genes in clusters based on a protein–protein interaction database, STRING (Table 1)47. The expected interaction and p value are calculated based on a random background model that preserves the degree distribution of the input proteins47,48, implemented via the get-summary function in the STRINGdb package. The pathway analysis was performed using the clEnrich function based on KEGG gene sets and visualized with Enrichr program49,50. For network analysis, a novel web-based tool, OmicsNet (, was used51.

Drug repositioning based on co-expression analysis

Each of the co-expressed gene clusters were subjected to drug repositioning analysis based on CMap gene sets to identify the likelihood of drug MOA in identified pathways. The statistical analyses were performed using R version 3.5.152. All significant thresholds were set at a two-sided p-value of 0.05.


  1. 1.

    Strober, W., Fuss, I. & Mannon, P. The fundamental basis of inflammatory bowel disease. J. Clin. Investig. 117, 514–521 (2007).

    CAS  PubMed  Google Scholar 

  2. 2.

    Hanauer, S. B. et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. Lancet 359, 1541–1549 (2002).

    CAS  PubMed  Google Scholar 

  3. 3.

    Rutgeerts, P. et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126, 402–413 (2004).

    CAS  PubMed  Google Scholar 

  4. 4.

    Sandborn, W. J. et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann. Intern. Med. 146, 829–838 (2007).

    PubMed  Google Scholar 

  5. 5.

    Lamb, C. A., O’Byrne, S., Keir, M. E. & Butcher, E. C. Gut-selective integrin-targeted therapies for inflammatory bowel disease. J. Crohn’s Colitis 12, S653–S668 (2018).

    Google Scholar 

  6. 6.

    Sandborn, W. J. et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 353, 1912–1925 (2005).

    CAS  PubMed  Google Scholar 

  7. 7.

    Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Danese, S. New therapies for inflammatory bowel disease: From the bench to the bedside. Gut 61, 918–932 (2012).

    CAS  PubMed  Google Scholar 

  9. 9.

    Kordjazy, N. et al. Role of toll-like receptors in inflammatory bowel disease. Pharmacol. Res. 129, 204–215 (2018).

    CAS  PubMed  Google Scholar 

  10. 10.

    Lu, Y., Li, X., Liu, S., Zhang, Y. & Zhang, D. Toll-like receptors and inflammatory bowel disease. Front. Immunol. 9, 72 (2018).

    PubMed  PubMed Central  Google Scholar 

  11. 11.

    Moschen, A. R., Tilg, H. & Raine, T. IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting. Nat. Rev. Gastroenterol. Hepatol. 16, 185–196 (2019).

    CAS  PubMed  Google Scholar 

  12. 12.

    Laroui, H. et al. Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. PLoS ONE 7, e32084 (2012).

    ADS  CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Esposito, G. et al. Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-alpha activation. Gut 63, 1300–1312 (2014).

    CAS  PubMed  Google Scholar 

  14. 14.

    Christensen, B. et al. Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 17, 486–493 (2019).

    CAS  PubMed  Google Scholar 

  15. 15.

    Reilly, C. M., Regna, N. & Mishra, N. HDAC inhibition in lupus models. Mol. Med. 17, 417–425 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Hancock, W. W., Akimova, T., Beier, U. H., Liu, Y. & Wang, L. HDAC inhibitor therapy in autoimmunity and transplantation. Ann. Rheum. Dis. 71(Suppl 2), i46-54 (2012).

    CAS  PubMed  Google Scholar 

  17. 17.

    Waibel, M. et al. Manipulation of B-cell responses with histone deacetylase inhibitors. Nat. Commun. 6, 6838 (2015).

    ADS  CAS  PubMed  Google Scholar 

  18. 18.

    Choo, Q. Y., Ho, P. C. & Lin, H. S. Histone deacetylase inhibitors: New hope for rheumatoid arthritis?. Curr. Pharm. Des. 14, 803–820 (2008).

    CAS  PubMed  Google Scholar 

  19. 19.

    Young, D. A. et al. Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res. Ther. 7, R503-512 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Chung, Y. L., Lee, M. Y., Wang, A. J. & Yao, L. F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8, 707–717 (2003).

    CAS  PubMed  Google Scholar 

  21. 21.

    Gray, S. G. & Dangond, F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 1, 67–75 (2006).

    PubMed  Google Scholar 

  22. 22.

    Sun, X. Y., Shi, J., Han, L., Su, Y. & Li, Z. G. Anti-histones antibodies in systemic lupus erythematosus: Prevalence and frequency in neuropsychiatric lupus. J. Clin. Lab. Anal. 22, 271–277 (2008).

    PubMed  PubMed Central  Google Scholar 

  23. 23.

    Li, N. et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc. Natl. Acad. Sci. USA. 105, 4796–4801 (2008).

    ADS  CAS  PubMed  Google Scholar 

  24. 24.

    el Assem, S. et al. Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction. Int. Immunopharmacol. 8, 1793–1801 (2008).

    CAS  Google Scholar 

  25. 25.

    Tao, R. et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13, 1299–1307 (2007).

    CAS  PubMed  Google Scholar 

  26. 26.

    Glauben, R. et al. Histone deacetylases: Novel targets for prevention of colitis-associated cancer in mice. Gut 57, 613–622 (2008).

    CAS  PubMed  Google Scholar 

  27. 27.

    Glauben, R. et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176, 5015–5022 (2006).

    CAS  PubMed  Google Scholar 

  28. 28.

    Segain, J. P. et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: Implications for Crohn’s disease. Gut 47, 397–403 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Edens, R. E., Dagtas, S. & Gilbert, K. M. Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: A comparative study. Int. Immunopharmacol. 6, 1673–1681 (2006).

    CAS  PubMed  Google Scholar 

  30. 30.

    Colombo, M. L. & Bosisio, E. Pharmacological activities of Chelidonium majus L. (Papaveraceae). Pharmacol. Res. 33, 127–134 (1996).

    CAS  PubMed  Google Scholar 

  31. 31.

    Kim, D. S. et al. The therapeutic effect of chelidonic acid on ulcerative colitis. Biol. Pharm. Bull. 35, 666–671 (2012).

    CAS  PubMed  Google Scholar 

  32. 32.

    Harris, N. R., Specian, R. D., Carter, P. R. & Morgan, G. A. Contrasting effects of pseudoephedrine and papaverine in dextran sodium sulfate-induced colitis. Inflamm. Bowel Dis. 14, 318–323 (2008).

    PubMed  Google Scholar 

  33. 33.

    Xu, S. et al. Piperlongumine inhibits the proliferation, migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Inflamm. Res. 67, 233–243 (2018).

    CAS  PubMed  Google Scholar 

  34. 34.

    Sanchez-Hidalgo, M., Martin, A. R., Villegas, I. & de la Lastra, C. A. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Eur. J. Pharmacol. 562, 247–258 (2007).

    CAS  PubMed  Google Scholar 

  35. 35.

    Sanchez-Hidalgo, M., Martin, A. R., Villegas, I. & Alarcon De La Lastra, C. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem. Pharmacol. 69, 1733–1744 (2005).

    CAS  PubMed  Google Scholar 

  36. 36.

    Celinski, K. et al. Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis. J. Physiol. Pharmacol. 63, 631–640 (2012).

    CAS  PubMed  Google Scholar 

  37. 37.

    Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41, 199–204 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).

    PubMed  PubMed Central  Google Scholar 

  39. 39.

    Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003).

    PubMed  MATH  Google Scholar 

  40. 40.

    Wang, X. et al. An R package suite for microarray meta-analysis in quality control, differentially expressed gene analysis and pathway enrichment detection. Bioinformatics 28, 2534–2536 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Smyth, G. K., Ritchie, M., Thorne, N. & Wettenhall, J. LIMMA: Linear models for microarray data. In Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Statistics for Biology and Health. (2005).

  42. 42.

    Jia, Z. et al. Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery. BMC Genom. 17, 414 (2016).

    Google Scholar 

  43. 43.

    Rousseeuw, P. J. & Kaufman, L. Finding Groups in Data (Wiley Online Library, Hoboken, 1990).

    MATH  Google Scholar 

  44. 44.

    Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572–1573 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Lamb, J. et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006).

    ADS  CAS  PubMed  Google Scholar 

  46. 46.

    Lamb, J. The Connectivity Map: A new tool for biomedical research. Nat. Rev. Cancer 7, 54–60 (2007).

    CAS  PubMed  Google Scholar 

  47. 47.

    Szklarczyk, D. et al. STRING v10: Protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447-452 (2015).

    CAS  PubMed  Google Scholar 

  48. 48.

    Pradines, J. R., Farutin, V., Rowley, S. & Dancik, V. Analyzing protein lists with large networks: Edge-count probabilities in random graphs with given expected degrees. J. Comput. Biol. 12, 113–128 (2005).

    CAS  PubMed  Google Scholar 

  49. 49.

    Kuleshov, M. V. et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90-97 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Chen, E. Y. et al. Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 14, 128 (2013).

    Google Scholar 

  51. 51.

    Zhou, G. & Xia, J. OmicsNet: A web-based tool for creation and visual analysis of biological networks in 3D space. Nucleic Acids Res. 46, W514-w522 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  52. 52.

    52Venables, W. & Smith, D. An Introduction to R. (2020).

Download references


This research was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF), which is funded by the Korean Ministry of Science, ICT and Future Planning [Grant number NRF-2019R1C1C1003524].

Author information




M.S.K. planned the study. M.S.K., H.H.L. and J.M.C. designed the study and drafted the manuscript. M.S.K., H.P.S., J.W.J., J.Y.Y. and H.H.L. conducted data collection, analysis, and interpretation. All authors revised the manuscript critically for important intellectual content and approved the final version.

Corresponding author

Correspondence to Min Seob Kwak.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kwak, M.S., Lee, H.H., Cha, J.M. et al. Novel candidate drugs in anti-tumor necrosis factor refractory Crohn’s diseases: in silico study for drug repositioning. Sci Rep 10, 10708 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing